Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that patients with alopecia areata in the US incur significantly higher healthcare utilization and expenses, primarily driven by ambulatory and pharmacy costs, compared to matched controls.

This study estimated the economic burden of alopecia areata in Romania for 2022, finding costs of 46.289 million EUR for adult and 1.89 million EUR for pediatric cases.

In this study, researchers analyzed data from Spain to find that alopecia areata is more prevalent in adults, with a point prevalence of 0.44% in 2021; they also noted significant healthcare costs and comorbidities, highlighting an unmet treatment need given limited systemic treatment use.

This study reported that alopecia areata imposes a significant personal and national economic burden in Japan, with estimated total costs of 112.7 billion yen due largely to productivity loss.

Alopecia areata significantly strains healthcare and finances in the UAE, needing better management.

This study analyzed the economic burden of alopecia areata in Saudi Arabia, finding significant costs driven by productivity loss and drug expenses, with severe cases incurring higher expenses, emphasizing the need for better treatment protocols and access to therapies.

This analysis highlights the substantial financial burden AA creates in Saudi Arabia, emphasizing the importance of early diagnosis and standardized treatment protocols to improve resource allocation and patient outcomes.

In this study, a survey in Norway and Sweden among adults with self-reported alopecia areata revealed a substantial economic burden with annual mean costs of €7,677 in Norway and €12,582 in Sweden, largely due to indirect costs from reduced productivity.

This study estimates the total cost of evaluating and treating polycystic ovary syndrome in reproductive-aged women in the United States to be $4.36 billion, suggesting more liberal screening could be beneficial.

This study found that among Korean patients with pattern hair loss, the subjective severity of hair loss and socio-psychological stress influenced their expenditure and quality of life, rather than the clinical severity.

This study found that patients with telogen effluvium who delayed hair washing or collected shed hair were more likely to have higher clinical severity and increased disease-related economic burdens, suggesting these behaviors can aid clinical assessments.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This study found that US adolescents with alopecia areata, especially those with alopecia totalis or universalis, experience significantly higher healthcare costs and resource use compared to matched controls.

This review discusses the psychological and economic impact of alopecia areata in Asia, highlighting significant quality of life reductions and a substantial financial burden on patients without providing new clinical results.

This study conducted in the Kingdom of Saudi Arabia reported that severe alopecia areata presents significant treatment challenges due to limited therapies, leading to substantial impacts on patients' quality of life, mental health, and economic burdens.

This research outlines a protocol for a systematic review to map the evidence on alopecia areata in Sub-Saharan Africa, aiming to identify research gaps and guide future studies and policy decisions related to this condition in the region.

This review highlights that alopecia areata significantly impacts mental health and finances, with patients facing depression, anxiety, and substantial out-of-pocket expenses due to limited insurance coverage.

In this review, the authors explore how wigs can significantly improve the quality of life for individuals with alopecia areata by providing emotional benefits and serving as a coping mechanism for hair loss, while also addressing economic considerations and potential barriers to their use.

This study reported that women with alopecia often face high out-of-pocket costs for over-the-counter treatments and camouflaging agents due to insufficient insurance coverage, which can significantly impact their financial well-being and ability to afford basic necessities.

This study reported that despite the limited effectiveness of many current therapies for alopecia areata, patients face substantial financial burdens managing the condition, based on an analysis of ten studies involving approximately 16,000 patients.

This study found that the prevalence of statin users in South Korea increased annually by 12%, with those having comorbidities like coronary disease and diabetes incurring higher medical costs.

This analysis found that females have a higher lifetime risk of alopecia areata across various regions and time periods, with increased risk associated with higher socio-demographic index levels.

This study in the United Arab Emirates found that alopecia areata significantly impacts patient quality of life and healthcare resource utilization, particularly among those with higher scalp hair loss.

This review discusses the economic burden of alopecia areata in adolescents and reports no new results; the authors note that evidence in this area is limited.

This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

The authors highlight the need for further research into the link between SARS-CoV-2 variants and long COVID, emphasizing the importance of developing personalized therapies to tackle the significant medical and economic burdens posed by long COVID.

This case report describes significant therapeutic effects from Tofacitinib Citrate Sustained-Release Tablets in a patient with Alopecia Areata, while highlighting the economic burden of long-term treatment.